Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David Hangauer is active.

Publication


Featured researches published by David Hangauer.


Tetrahedron Letters | 1983

Addition of trimethylsilyl cyanide to α-substituted ketones: Catalyst efficiency

William J. Greenlee; David Hangauer

Abstract Addition of trimethylsilyl cyanide to α-substituted ketones is often slow and incomplete when catalyzed by zinc iodide. Use of potassium cyanide/18-crown-6 complex as catalyst is a superior method, providing high yields of adducts.


Tetrahedron Letters | 1986

Total synthesis of erbstatin

David Hangauer

Abstract The total synthesis of erbstatin in six steps and 38% overall yield from commercially available lactone 1 is presented.


Annals of the New York Academy of Sciences | 1985

Modeling the Mechanism of Peptide Cleavage by Thermolysin

David Hangauer; Peter Gund; Joseph D. Andose; Bruce L. Bush; Eugene M. Fluder; Eugene F. McIntyre; Graham M. Smith

Merck & Co. has for some time utilized a molecular modeling system that we developed for aiding drug design.’.’ More secently, it became clear that more powerful systems were needed to study the relevant larger structures which were becoming increasingly available, and to study steric and electrostatic surfaces. We have obtained such equipment and utilized it for drug design. At the same time, realizing that many of the modeling functions can be performed on less expensive equipment, we have modified our program to run on several types of graphics terminals. Characteristics of our current system for molecular modeling, and some applications to drug design, are discussed below.


Archive | 1991

Imidazole angiotensin ii antagonists incorporating a substituted benzyl element

William J. Greenlee; Arthur A. Patchett; David Hangauer; Thomas F. Walsh; Kenneth J. Fitch; Ralph A. Rivero; Daljit S. Dhanoa


Archive | 1991

Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists incorporating a substituted benzyl element

William J. Greenlee; David Hangauer; Arthur A. Patchett; Thomas F. Walsh; Kenneth J. Fitch; Daljit S. Dhanoa; Ralph A. Rivero


Archive | 1991

Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring

William J. Greenlee; Arthur A. Patchett; David Hangauer; Thomas F. Walsh; Kenneth J. Fitch; Ralph A. Rivero; Daljit S. Dhanoa


Archive | 1982

Antihypertensive proline derivatives

William J. Greenlee; David Hangauer; Arthur A. Patchett


Drug Information Journal | 1984

INTERMOLECULAR MODELING METHODS IN DRUG DESIGN/ MODELING THE MECHANISM OF PEPTIDE CLEAVAGE BY THERMOLYSIN

Graham M. Smith; David Hangauer; Joseph D. Andose; Bruce L. Bush; Eugene M. Fluder; Peter Gund; Eugene F. McIntyre


Archive | 1982

Urea compounds as antihypertensives.

Arthur A. Patchett; William J. Greenlee; David Hangauer


Archive | 1991

Antagonistes d'angiotensine ii incorporant un element benzylique substitue

William J. Greenlee; Arthur A. Patchett; David Hangauer; Thomas F. Walsh; Kenneth J. Fitch; Ralph A. Rivero; Daljit S. Dhanoa

Researchain Logo
Decentralizing Knowledge